Key Takeaways
- Revlimid era ends, base business takes over: Q2 marks the last meaningful quarter of Lenalidomide revenue; Q3 onward, the company budgets nothing material from the product, shifting investor focus entirely to base business growth and pipeline execution.
- H2 PAT guided at ₹135–150 cr per quarter: Management provided explicit run-rate guidance of ₹750–800 cr revenue and ₹135–150 cr PAT for the next six months, consistent with full-year PAT of ₹1,275–1,300 cr, as exclusivity-driven upside recedes until FY28.
- Adcock Ingram deal closed, consolidation begins: The acquisition completed with delisting finalized days before quarter-end; only partial profit consolidation this quarter, with full associate consolidation (36% stake) starting Q3, adding a stable, non-US earnings stream bought at 10–12x EBITDA.
- Semaglutide India filing on track for March–April 2026 launch: Clinical trials expected to complete in December, filing targeted for early January, with management aiming to be in the first generic wave; the US opportunity, partnered with Viatris, is described as "100x" larger but remains a few years away.
- What to watch next quarter: Whether the ₹135–150 cr quarterly PAT run rate holds without Revlimid, the pace of Adcock profit consolidation, and any update on the three to four Para-IV filings planned in the coming months.
Revlimid: The End of a Windfall
- Q2 was the last meaningful quarter: Management stated explicitly that Q3 and Q4 are not expected to have much revenue from Lenalidomide, citing increased competition and uncertainty about market share; budgeting does not include much from this product.
- Future sales will be residual only: The company will get some sale in multiple markets but driven by high competition; management is not giving aggressive guidance and expects nothing material going forward.
- Base business must now carry the P&L: With the exclusivity windfall over, the investment case shifts to whether the underlying portfolio can deliver the guided 10–15% annual base business growth, with 50–60% profit jumps only in years when new exclusivities kick in.
Rajeev Nannapaneni: "I think this quarter we have done extremely well. I think that is reflected in the numbers. Regarding Q3 and Q4, we are not expecting much. I think we are seeing more competition. I am not expecting much. I think in our budgeting, we have not kept much revenue from Lenalidomide."
Pipeline & Launches: A Dull FY27, Then a Pickup
- US launches back-end loaded: Management expects only one or two launches in FY26–27, describing the year as "a little dull," with bigger launches concentrated in FY27–28 and beyond; specific product names were withheld citing confidentiality.
- Para-IV filings accelerating: The company intends to file another three or four products in the next few months, though it is unsure if any will be sole first-to-file; these are part of a strategy to keep doing "something innovative all the time" to capture the next jackpot.
- FTF pipeline spans several years: Key first-to-file opportunities include Semaglutide (few years away), Ibrutinib (few years away), Olaparib, and Erdafitinib; post-March 2027, some smaller FTFs will start contributing.
- China tender win is immaterial: Natco won a government tender from China for Olaparib, but at a cutthroat price; not financially material.
Rajeev Nannapaneni: "I think you should expect in '26, '27 we will have one or two, but bigger launches are happening in '27, '28. So, '26, '27 will be a little dull, but I think '27, '28 on, things will pick up."
Semaglutide: India First, US Later
- India launch timeline is specific and near-term: Clinical trials expected to complete in December, filing targeted for early January, with launch anticipated around March–April 2026; management hopes to be in the first generic wave.
- India economics are modest: Generics will have a substantial price advantage versus the innovator, which will increase market size, but the market will be very competitive; the first wave will allow some money and brand building but is "not a jackpot."
- US is the real prize, but distant: The US opportunity is described as "100x difference" versus India; the thrust will be mostly on the US and other regulated markets via the Viatris partnership, but the regulatory file is still under review with queries being answered, and launch is a few years away.
- International opportunities are limited near-term: Canada rights were given to Viatris so Natco is not in the first wave there; South Africa's patent opens later; Brazil's dossier is not advanced enough to give timelines.
Rajeev Nannapaneni: "US, any day. US, by far. There is no comparison. It is 100x difference."
Adcock Ingram: Diversification at a Rational Price
- Deal closed, delisting complete: Adcock Ingram is now a private company with only two shareholders: Bidvest and Natco; delisting happened only a few days before quarter-end, so only partial profit consolidation occurred this quarter.
- Accounting treatment: Adcock becomes a long-term investment in non-current assets, includes a goodwill element with some small amortization; profits will be shown as an associate (not controlled entity) since Natco does not own 51%; next quarter will consolidate a full quarter at approximately 36%.
- Acquisition math favors South Africa over India: Management noted that Indian pharma assets trade at 30–40x EBITDA, while Adcock was bought at 10–12x EBITDA; the asset must perform 3–4x better just to match what an equivalent Indian investment would have returned, but it diversifies away from the US-dependent volatile business into a stable cough-and-cold portfolio.
- Growth expectations are long-dated: Management declined to speak about Adcock's turnover growth expectations "right now" since they just got into the asset, but expects good growth long-term by adding India pipeline and licensing products from partners; substantial growth is a long-term, not near-term, story.
Rajeev Nannapaneni: "That asset has to perform 4x better than just to meet my South Africa investment."
Base Business & Segments: Steady, With Niche Wins
- Domestic business stable with new launches: Risdiplam launched and doing reasonably well; not a large product but strengthens the base business; the Spinal Muscular Atrophy product is small and niche, with Natco currently the only generic in the market, giving entry into the neurology segment.
- CTPR combinations approaching breakeven: The CTPR business has grown to about ₹52 crores and is now close to EBITDA positive (give or take R&D expense), whereas earlier it was losing money; management plans to demerge this business from the main company and list it separately.
- ROW markets performing: Brazil's first generic of Carfilzomib is doing reasonably well; Saudi Arabia is doing well; Canada business improved after the warning letter at Kothur was lifted, enabling more supplies.
- Crop/agro demerger announced: The company is planning to demerge and list the crop/agro entity separately, with listing possibly sometime in 2026 once all clearances come through; management said value unlocking numbers are "very hard to predict right now."
Capital Allocation & Investments
- Balance sheet crossed ₹10,000 cr in assets: The balance sheet has grown dramatically over the last 7–8 years despite a challenging period; the company still has substantial cash even after the Adcock acquisition and remains open to opportunities including in the US.
- Small disruptive investments continue: Natco holds investments in Cellogen, Stro Therapeutics, and eGenesis (genetically engineered pig kidney transplants); these are finite, not exceeding ₹40–50 cr per year, though management is open to increasing if opportunity arises.
- US takeover question went unanswered: An analyst asked about a previously mentioned takeover in the US; management asked for clarification and the exchange ended without a response; on a separate question, management said "we are looking at different investment options" without confirming or denying any specific deal.
Rajeev Nannapaneni: "I mean, obviously the biggest exciting one is the eGenesis one, which is the kidney transplant, where they are taking a genetic engineered pig and putting it in a human. And one of the patients actually lived for more than six months and another patient is still comfortable, so, he is on the pig kidney. So, these are very disruptive investments, my friend."
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| Quarterly revenue run rate | ₹750–800 cr per quarter | Q3 FY26 and Q4 FY26 |
| Quarterly PAT run rate | ₹135–150 cr per quarter | Q3 FY26 and Q4 FY26 |
| Full-year PAT | ₹1,275–1,300 cr | FY26 |
| Base business growth | 10–15% annual growth | Ongoing, annual |
| Semaglutide India filing | File for approval | Early January 2026 |
| Semaglutide India launch | First generic wave | March–April 2026 |
| Para-IV filings | Three to four new filings | Next few months |
| US launch pickup | Bigger launches begin | FY27–28 |
| Adcock profit consolidation | Full quarter as associate (36%) | Q3 FY26 onward |
| CTPR demerger and listing | Separate listing of demerged entity | Possibly sometime in 2026 |
| Crop/agro demerger and listing | Separate listing of demerged entity | Possibly sometime in 2026 |
Key Metrics
| Metric | Q2 FY26 |
|---|---|
| Consolidated total revenue | ₹1,463 cr, versus ₹1,434.9 cr in Q2 FY25 |
| EBITDA | ₹679.2 cr, margin at 46.4% |
| PAT (H1 FY26) | ₹998 cr (per management) |
| Full-year PAT guidance | ₹1,275–1,300 cr, H2 guidance of ₹275–300 cr |
| Quarterly revenue run-rate guidance (H2) | ₹750–800 cr per quarter |
| Quarterly PAT guidance (H2) | ₹135–150 cr per quarter, including Adcock Ingram |
| Interim dividend | ₹1.5 per equity share of ₹2 face value |
| API segment revenue | ₹53.9 cr |
| CTPR (Crop Health) business revenue | ₹52 cr, close to EBITDA positive |
| Base business growth expectation | 10–15% per year |
| Net cash expected post-Adcock acquisition | ₹2,700–2,800 cr, spent ₹1,600 cr cash on Adcock, borrowed ₹400 cr |
| Adcock Ingram steady-state sales | US$550 million, PAT around US$46 million, Natco consolidates ~36% |
| Adcock Ingram acquisition multiple | 10x–12x EBITDA |
| South Africa contribution to base earnings | 25–30% expected |
| R&D and small investments annual spend | ₹40–50 cr per year, not exceeding |